|

AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy

RECRUITINGSponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University
Actively Recruiting
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Started2025-01-01
Est. completion2026-06-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07263204

Summary

By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic subtypes-while simultaneously differentiating HCM from hypertensive heart disease, aortic stenosis, and other phenocopy disorders.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Adults aged ≥ 18 years.
2. HCM cohort: Adults diagnosed with hypertrophic cardiomyopathy in accordance with the \*2023 Chinese Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy in Adults\*.
3. HCM phenocopy cohort: Adults with an LV wall thickness ≥ 13 mm at any site on echocardiography.
4. Healthy-control cohort: Adults with no history of cardiac disease and no evidence of myocardial hypertrophy on echocardiography.

Exclusion Criteria:

Patients from whom analyzable ECG data cannot be obtained.

Conditions3

Heart DiseaseHypertrophic Cardiomyopathy (HCM)Left Ventricular Hypertrophy

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.